Lisata Therapeutics
LSTA
22 hedge funds and large institutions have $2.17M invested in Lisata Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 14 reducing their positions, and 15 closing their positions.
4.98% more ownership
Funds ownership: 1.04% → 6.02% (+5%)
35% less funds holding
Funds holding: 34 → 22 (-12)
57% less capital invested
Capital invested by funds: $5M → $2.17M (-$2.83M)
79% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 14
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$89.4K |
| 2 |
CW
Cook Wealth
Raleigh,
North Carolina
|
+$88.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$20.2K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$841 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$673K |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$399K |
| 3 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$73K |
| 4 |
Renaissance Technologies
New York
|
-$53.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$46K |
LSTA Hedge Fund Activity: Q3 2022 in Review
22 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2022, worth a combined $2.17M — down 57% from $5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LSTA and 3 opened new positions — a net loss of 12 holders — while 14 trimmed existing stakes and 3 added.
The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $89.4K. The largest seller was Sabby Management, cutting an estimated $673K.
- 22 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2022, down from 34 in Q2 2022.
- Funds reported $2.17M of Lisata Therapeutics stock for Q3 2022, down 57% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q3 2022 and 15 closed out, a net change of -12 holders.
- The largest Lisata Therapeutics buyer in Q3 2022 was Dimensional Fund Advisors, an estimated $89.4K added.
- The largest Lisata Therapeutics seller in Q3 2022 was Sabby Management, an estimated $673K sold.
Based on aggregated 13F filings for Q3 2022.